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ABSTRACT 
Oral contraceptives are widely used hormonal contraceptives compared to other dosage forms. There are modifications of hormonal contraceptives 
dosage forms to reduce side effects and improve effectivity and compliance during contraceptive usage. The implantable drug delivery system is a 
suitable contraception technique for women who are difficult to recall the time of use, such as pills. The contraceptive implant is a small size of rod, 
and it is placed in the upper arm subcutaneously. Many advantages by using contraceptive implants, such as high effectivity, easy to use, free from 
estrogen influences, fast recovery of the normal ovulatory cycle, safe for breastfeeding women, and safer for women that have the certain medical 
condition. However, implant removal procedures are becoming the problem because it requires trained personnel. The unscheduled period is also 
one of the disadvantages of implants. Although for most women, the implant could reduce blood loss when the period, for some cases it could 
prolong the period of time. In this article, we reviewed implant contraceptives development due to its application increased rapidly in the last 
decade. The history of implants, advantages, and disadvantages, and marketed products of the implant were also described in this article. The 
challenges and opportunities of the contraceptive implant development were summarized based on literature. Designing in situ forming implant 
and polymeric implant for contraception could be the great future in contraceptive implant development. Finally, contraceptive implants are 
promising hormonal contraception dosage forms to develop in unintended pregnancies prevention over the world. 
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Over the last 35 y, the use of contraceptive implants has been used by 
millions of women all over the world and permitted in more than sixty 
countries. Its high efficacy and easy applicability led implants 
becoming a prior choice as hormonal contraceptives for women. 
Contraceptive implants have a high progression rate compared with 
other dosage forms and also have a very high efficacy which 
prevalence of unintended pregnancies are less than 1 per 100 women 
in a year. Over 5 y, there were 2 million unintended pregnancies 
avoided with the contraceptive implant usage. Nowadays, the use of 
short-acting contraceptive dosage forms, such as oral or injection 
contraceptive, is switched into contraceptive implants [1, 2]. 
Implants usage were registered in more than 100 countries around 
the world, Indonesia has many users of it, where its use for the last 
decade has increased rapidly. Over 5 y, the use of the contraceptive 
implant increased and more than 15-fold in Ethiopia and Rwanda, 4-
fold in Tanzania, and 2-fold in Malawi [3, 4]. 
Contraceptive implants in most countries were available in two 
types: the single-rod implant of etonogestrel and two-rod implant of 
levonorgestrel. Pharmacological profile and physical effects of those 
contraceptive implants were same. The product of two-rods 
contraceptive implant was Sino-implant (II) and Jadelle, while 
the single-rod contraceptive implant was Implanon. Contraceptive 
implants are very effective and safe to use as well as a contraception 
method with a long duration of action [5, 6].  
However, implant removal procedures were becoming the problem 
because it requires trained personnel. To overcome this problem, 
contraceptive implants were developed degradable polymer as a 
carrier. The use of degradable polymer could make the matrix 
degrade into monomers and by-products that can be cleared by the 
body without removal procedures after the duration of therapy was 
completed [7]. The literature used in this review was obtained from 
PubMed, Google Scholar, and Science Direct search engine without 
year based restriction but we prefer to select the latest article. 
Brief history of implants 
In the 1930s, there was a pellet containing hydrophobic compounds 
with continuous drug release. This pellet system including estradiol 
pellets for prostate cancer treatment and testosterone pellets for 
testosterone deficiency treatment. In addition, the formulation of 
drugs or esters with very poor aqueous solubility can also offer an 
extended drug delivery system [8]. 
The history of implantable drug delivery systems began by Deansby 
and Parkes research in 1983. They were investigated how 
compressed pellets of estrone affected castrated male chicken that 
inserted subcutaneously. In the 1960s, Folkman and Long pioneered 
the formulation of the implant. They were designed as a polymeric 
membrane from silicone rubber to control the release rate of the 
drug. The silicone rubber was made into capsules and filled with 
various drugs, then inserted into the cardiac muscle of dogs. The 
result showed that the formulation was succeeded to deliver various 
drugs into the target and the capsules were biocompatible. In 
addition, the formulation became the basic formula for implantable 
drug delivery systems [9–11]. Since these first few years, the 
implantable drug delivery system research has increased. The 
formulation was developed by using various drugs, implantation 
technique, carriers (more bioerodible and biostable), and 
implantation sites [12]. 
In the early 1960s, T. Higuchi proposed the "Higuchi equation" [1]. 
Initially, this equation is applied to ointment drug release but then 
applied to drug release of various matrix systems. This equation 
showed that extended drug release could be perceived from 
dispersed solid in the matrix, but the half-life would be varied. 
Mt/M∞= 2 [DCs(2C0–Cs)t]1/2/C0
In this equation, C0 is the total concentration, D is the diffusivity and 
Cs is the drug solubility in the matrix. The surface area is A and depot 
thickness is l. This equation explained the rectangular piece release, so 
∞ = AlC0. The model mentioned above represented the dosage forms 
which the rate limiting step was drug diffusion rate through the matrix 
system. It was assumed that the drug was transported rapidly through 
the surface diffusion boundary layer of the system [13]. 
l [1] 
Implantable drug delivery systems are designed to diminish or avoid 
the problems linked with oral (powder, gel, tablet, or liquid) dosage 
form administration. Various design methodologies have been 
pursued based on drug development at that time [12]. Improving 
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safety and efficacy is the main goal of any design methodology. It 
was made by adjusting dose rate and dose at the chosen site. 
There was the problem linked with oral dosage forms [9]: 
• Drug bioavailability — drug solubility is low, so the amount of 
drug absorbed is also low 
• Drug stability — most of the drugs are not stable when delivered 
orally because of GITs condition 
• Drug toxicity — because of poor physicochemical properties of 
drugs, the dose must be increased. Therefore the unacceptable side 
effects arise. 
• Duration of release — it is hard to formulate the oral dosage 
form in order to release slowly for more than 24 h. 
• Drug half-life is too short — drug potency loses quickly so it 
becomes less effective. 
Contraceptive implant 
The contraceptive implant is a small size of rod, and it is placed 
in the upper arm subcutaneously.  
It could release hormones such as progesterone slowly into the 
bloodstream in a long time period, months or even until 5 y. Its 
effectivity decreased in women who have a disease or bleeding 
disorders [14]. 
Contraceptive implants as a long-acting reversible dosage forms 
It was predicted that about half of pregnancies in England and other 
high-income countries are expected as a result of unintended 
pregnancy [15]. These problems came because of the use of less 
effective contraceptive dosage forms, such as condoms and pills. 
Contraceptive implants were long-acting reversible dosage forms, so 
it was expected to prevent or delay pregnancies [16]. 
Long-acting reversible contraception was predetermined by 
National Institute for Health and Care Excellence as a hormonal 
contraception method which the administration required was once 
per cycle or even less. It was including intrauterine copper (given 
every 5-10 y), subdermal implants of progestin (given every 3-5 y), 
the combination of the vaginal ring (requires administration every 4 
w), intrauterine progestin system (given every 3-5 y), and injectable 
progestin (given every 8-13 w) [17].  
The prevalence of contraceptive implants usage 
Although there have been millions of implants worldwide, it still has 
the low prevalence usage. The prevalence of implants usage in 
women is 18% worldwide, and the highest prevalence of it was in 
India, about 36%[18]. At 2010, only 2.6% of women (<30 y) used the 
implants in France [19]. Meanwhile, in 2008, women of childbearing 
age in the United Kingdom that used the implant for their 
contraception were about 1–2% [20]. Columbia, Burkina Faso, 
Norway, Rwanda, and Ethiopia have succeeded countries in 
increasing the prevalence of contraceptive implants usage more 
than 3% of women of childbearing age [18].  
Advantages of Implant Contraception 
The advantage of implants is high effectivity (miscarriage rate: <1%) 
and easiness of use. After the insertion procedure, there is no further 
handling up to removal procedure time. Therefore, the implant is 
suitable contraception technique for women who are difficult to 
recall the time of use, such as pills. In addition, the implant does not 
interfere with the copulatory activity, because it is inserted on the 
subdermal of the upper arm. Even though the implant is tangible 
below the skin and gives a small scar, providing contraceptive 
supplies at home is not required. The user also does not need to 
refill the contraception or follow-up for contraception in the short 
term. Contraceptive implants are free from estrogen influences. 
Women with estrogen hormone contraindications, very appropriate 
to use contraceptive implants. As a consequence women that have 
certain medical conditions such as hypertension, venous thrombotic 
or family history of inherited thrombophilia may still use this 
contraception method [21,22].  
The woman that use implant can get the fertility back quickly. Most 
women recover their normal ovulatory cycle within the first month 
after the removal procedure. Pregnancy rates in the first year after 
removal procedure equals to pregnancy rates in women who do not 
use contraceptive methods and attempt to pregnant. There is no effect 
on long-term fertility in the future. In addition, implants do not 
constrain breast milk. Implants are the best method for breastfeeding 
women. There is no effect on the quality and quantity of breast milk, 
and the baby grows normally. If the newly breastfed mother does not 
have time to (within three months), the implant can be dispersed 
immediately Postpartum. Another benefit of the implant is blood loss 
when period reduced, so it can help prevent anemia [22]. 
Summary of implant benefit [9]: 
• Patient compliance — patient does not worry about dosing 
interval. 
• Fewer side effects — drug release in the body is controlled and 
the dose usually is lower with better control at the target site; side 
effects are reduced; drug concentration in the plasma is constant. 
• Lower dose — the drug does not meet first pass hepatic effects, 
before approaching the receptor. 
• Drug stability improved — the drug is protected from rapid 
metabolism. 
• Drug allergy — if the patient has an allergy or shows an adverse 
reaction to the drug, the implant could remove immediately. 
Disadvantages of implant contraception 
The main disadvantage of implants is an unscheduled period. 
Although for most women, the implant could reduce blood loss 
when the period, in uncommon cases it could prolong the period 
time [21]. There was a study evaluated bleeding after ENG 
implantation, the result showed that 22% had amenorrhea, 34% 
were rarely bleeding (bleeding or spotting), 7% were frequent 
bleeding, and 18% were excessive bleeding [23].  
Women who use implants more often complain about weight gain. 
Assessment of weight change in implant users is disrupted by 
changes in exercise, diet, and aging. Although appetite enhancement 
may be associated with the androgenic activity of levonorgestrel, 
low levels of implants may not have any clinical implications. In 
addition, continuous monitoring of 75 women using Norplant 
showed no body mass index improvement after five years [22, 24]. 
In addition, the prevalence of acne, dysmenorrhea, and endometriosis 
are increased in women with contraceptive implants. Acne is caused 
by the androgenic activity of levonorgestrel directly and it also 
decreases sex hormone binding globulin (SHBG), leading to elevated 
free steroids level (levonorgestrel or testosterone). Compared to 
combined oral contraceptives containing levonorgestrel, the estrogen 
increases SHBG levels, so free androgens is decreased. The literature 
stated that women who used ENG implants for 2 y, 16% of them 
experienced the incidence of new acne [25]. In another study that 
investigates the effect of ENG implants in endometriosis women, the 
mean score for dysmenorrhea increased from 7.08 to 0.84 at 12 w 
after implantation of ENG [21]. Other side effects include dizziness, 
headaches, nausea, rashes, and mood changes. In rare cases, the 
implant user may experience severe headaches or a migraine [22]. 
Contraceptive implant types 
a. Levonorgestrel implants (LNG implants) 
LNG Implant consists of two rods that were inserted using a 
disposable V trocar. Two products available were Sino-implant (II) 
and Jadelle. The size of rods was 2.5 × 43 mm and each rod 
containing 75 mg of LNG. Thin silicon (Silastic) wrapped the 
embedded LNG in siloxane copolymer. The original license of Jadelle 
was last for 3 y; but now in most countries, it was extended for 5 y, 
while the license of Sino-implant (II) was last for four years [5, 26].  
b. Etonogestrel implants (ENG implants) 
Implanon NXT/Nexplanon was single rod-shaped ENG 
implants (2 × 40 mm) that could be inserted easily because of its 
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special applicator. ENG microcrystal was embedded in a 68 mg 
matrix of EVAc copolymer, then it was covered by a membrane 
(thickness: 0.6 mm). Implanon NXT/Nexplanon contained 15 
mg of BaSO 4
 
; this radio-opaque implant was bioequivalent to 
Implanon[27]. ENG implant was very effective and safer. 
However, comparing the pregnancy rate between LNG and ENG 
implants, there was no significant difference between them [28, 
29].
Table 1: Products of contraceptive implant in the market 
Products Polymer Drug Ref. 
Norplant® Silicone Levonorgestrel  [30, 31] 
Jadelle® Silicon  Levonorgestrel  [31] 
Implanon® EVAc Etonogestrel  [32, 33] 
Sino-implant (II) ® Silicone  Levonorgestrel  [5] 
Nexplanon® Silicon Etonogestrel  [6] 
Capronor® PCL Levonorgestrel [34] 
 
Pharmacology  
The mechanism of action of the sub-dermal implant was included to 
prevent the ovulation, the sperm penetration in cervical mucus, and 
the implantation by attenuating the endometrium [35].  
Minimum effect concentration (MEC) of ENG was 90 pg/ml, and it 
was achieved within a few hours after insertion. After four to six 
months from insertion, the remaining plasma levels was almost 
constant. The study indicates that when ENG plasma levels were 
higher than MEC, it would inhibit the ovulation in 97% of women; 
this condition could be achieved within 8 h from insertion. So, it 
means that the effectivity could be ascertained since insertion. ENG 
plasma concentrations decreased slightly for 3 y (1,000 pg/ml to 
100 pg/ml) [26]. After the release, ENG plasma levels fall quickly, 
below the threshold for detection (20 pg/ml) over four days. Drug 
release of LNG implant generally similar to the ENG implant, causing 
their pharmacokinetic profile were almost identical [36]. 
Progestin contraceptive implants effectivity might be reduced by 
inducers such as antiretroviral therapy, some antibiotics, and some 
antiepileptic drugs [37]. Contraceptive implants should not be 
initiated in women who use narcotics for long-term. Additional 
precautions are recommended in patients with the use of inducer for 
28 d after termination.  
Insertion 
Timing of insertion  
Implants in women are used to avoid pregnancy; implant implantation 
can be used at any time during the woman's cycle. Implants are very 
effectively used/inserted during the first 5 d of the menstrual cycle, 
starting from the first day of menstruation. If the woman who is 
implanted is impaired by her menstrual cycle, a pregnancy test should 
be performed after 3 w. This implant is effective after 7 d if inserted at 
the time of the menstrual cycle. Thus, if the woman is having sexual 
intercourse, need to use another contraceptive like a condom for 7 d 
after installation. Alternative contraceptives are used with caution if 
need to be extended to 2 w [28]. 
If postpartum implantation is performed, implant insertion may be 
performed after 21 d postpartum. In this condition, there is no need 
for an extra precaution such as women with normal menstrual 
cycles. 15 Women who are breastfeeding for up to 6 mo postpartum, 
it can be assumed that the woman is not pregnant. Similarly, in 
women who have both first and second density abortions, implants 
can be performed within 5 d [28]. 
Insertion technique 
Early initial implant insertion is by local anesthesia; this is done so that 
insertion can be more effective. Implant insertion should be done 
carefully to avoid insertion into a muscle or nerve or blood vessel injury. 
Use of the applicator should be used with a 30 ° slope to the skin and 
thereafter immediately after the needle penetrates the dermis is lowered 
to the horizontal position. After the needle penetrates the skin, careful 
withdrawal of the needle until the subdermal plane is shallow. Then 
adjust the depth of the implant below the skin surface. After insertion, 
the health professional will verify the presence of the implant by 
palpation. Palpation is a method of examination in which the tester feels 
the size, strength, or location of something (from the part of the body 
where the examiner is a health practitioner). Documentation is ensured 
that the implant has been successfully inserted into the arm [28]. 
Side effects of insertion 
Side effects after insertion of contraceptive implants include 
bruising, pain, redness, or irritation. Infectious lesions (cellulitis) 
after insertion are not reported in an ENG implant trial, but 
sometimes cases of wound infections due to the implant insertion 
process need treatment with antibiotics. Side effects that occur after 
implantation can occur changes in vaginal bleeding patterns, 
including the absence of menstruation (amenorrhea), decreased sex 
drive, dizziness, inflammation experienced mood swings and 
depression, nausea or abdominal pain and weight gain [38]. 
Site of insertion 
For implant insertion regions ENG (Norplant) is recommended to be 
between the biceps and triceps muscles. The insertion is carried out 
8 to 10 cm above the medial humerus epicondyle area. For insertion 
of NXT Implanon inserted inside the upper arm to avoid large blood 
vessels and nerves located deeper in connective tissue. The insertion 
is carried out with low depth subdermal, to avoid the risk of 
neurovascular damage done by insertion or implant release [28]. 
Timing of remove 
After 3 y after insertion or after the implant has finished, the implant 
should be removed because the effectiveness of the implant is 
reduced. The implant release process performed is a similarly minor 
surgical process performed as in the implant insertion process [38]. 
Polymers of implant dosage forms 
Polymers used in implants broadly divided into two groups, namely 
non-degradable and degradable polymers. The non-degradable 
polymer used because it is relatively inert and biocompatible, and 
mechanism of the drug release system was diffusion or swelling 
[7,39]. Diffusion-controlled systems can be divided into the type of 
reservoir and matrix, while the systems swelling-controlled 
produced from water-soluble polymers which have cross-link bonds. 
Examples of non-degradable polymers were silicon, cellulose 
derivatives, and acrylic [7]. These polymers are suitable for long-
term use as bones and teeth implants [40]. 
Degradable polymer is safer to use because it can be degraded into 
monomers and by-products that are non-toxic for the body so that it 
can be cleared efficiently by the body. It didn’t need surgery for 
implants removal after the treatment is completed [7, 41]. 
Biodegradable implants with PLA and PLGA-based can flabbergast 
the weaknesses of non-degradable implants. This type of polymer is 
widely used as a surgical polymer and has been approved by the 
USFDA for parenteral administration. PLGA and PLA as the 
biodegradable carrier could be designed into an implant easily with 
some of the techniques [42]. These polymers also have 
disadvantages. The acidic by-products can undergo unwanted 
reaction. In addition, the cost of the implant with the biodegradable 
polymer is higher than non-degradable polymer [43]. Until now, 
Wathoni et al. 
Int J App Pharm, Vol 10, Issue 6, 2018, 16-22 
 
19 
some pharmaceutical products using degradable polymers have 
been approved by the USFDA. This system has been delivering 
various types of drugs such as hormones, antitumor, and antibiotics 
with complex drug release include diffusion and erosion [44, 45]. 
The physicochemical properties of the drug are the main key to 
determining drug release mechanism of PLA or PLGA-based 
implants. Implants show a large burst in initial release followed by a 
quick release. Drug loading also affects the drug release rate. As 
higher drug loading, as faster drug release from the polymer. Some 
drugs assimilated into the PLA or PLGA implants are purposed to be 
released at the target site, which is a benefit of drug delivery of PLA 
or PLGA-based implant [46].  
a. Polyethylene (PE) 
Polyethylene can be classified based on molecular weight, the high-
density (HDPE) and low-density (LDPE). As molecular weight increased, 
the material strength increased, but its elasticity decreased [47]. Porous 
HDPE has good elasticity, biocompatibility, and its anti-infective 
properties were strong enough to be used as the material in rhinoplasty 
surgery [48]. However, PE has a "plastic feel" when applied to the skin. 
Another PE that is often used in the controlled release system is poly 
(ethylene-co-vinyl acetate) or EVAc. It could deliver drugs with wide 
range molecular weight and also specifically used as a drug elution 
matrix. Products using EVAc as a polymer were Ocusert 
(pilocarpine implant for glaucoma, from Johnson and Johnson) and 
Implanon (etonogestrel implant, from Organon).  
b. Polyurethane (PU) 
Polyurethane widely used in implants and degraded in the body for 
a long time. However, if handled properly, the degradation can 
facilitate the growth of new tissue [49]. PU has a low water 
permeability, but this can be reduced with the addition of a low 
concentration of isopropyl myristate [50]. 
c. Silicone 
Silicone is an inert compound used in various applications and forms 
[47]. Silicon included into the most suitable polymer for the 
encapsulation of the body for the long-term period compared with 
polyurethane and other resins because of its surface energy was low 
and the topography was more subtle [51].  
Because of these characteristics, absorption of the cells and 
molecules by the polymer itself could be prevented. The most widely 
used of silicone derivative compounds in biomedical implants were 
parylene and polydimethylsiloxane (PDMS) [47].  
d. Polycaprolactone (PCL) 
Polycaprolactone, a semi-crystalline polyester, was highly-soluble in 
organic solvents, the glass transition temperature was-54 °C, and the 
melting point is 55-60 °C [52]. It's in vivo degradation rate was low 
but the drug permeability was high, so PCL would be suitable for 
long-term drug delivery [53].
 
Table 2: Advantages and disadvantages of polymer 
Polymer Advantages Disadvantages  Ref. 
PE  ▪ Resistant against chemical reactions 
▪ Mechanical properties can be modified based on its molecular weight 
▪ low melting point 
▪ HDPE porous are anti-infective, biocompatible, and elastic 
▪ Less comfortable due to 'plastic feel' when 
applied 
▪ Hard to dye 
▪ High coefficient of friction 
[47] 
PP  ▪ Good dielectric properties  
▪ two forms (copolymers and homopolymers) have different 
mechanical strengths  
▪ Non-toxic  
▪ High melting point  
▪ Non-degradable 
▪ semi-rigid → local discomfort to the patient 
▪ yet confirmed whether it was biocompatible or 
not 
[47] 
Silicone ▪ biocompatible  
▪ low toxicity 
▪ chemically inert 
▪ excellent electrical insulation 
▪ high gas permeability 
▪ heat stability 
▪ Hydrophobic  
▪ low thermal conductivity 
▪ PDMS 
o Clear 
o No flame 
▪ Parylene 
o Good conformation 
o Could form a thin layer with low coefficient of friction 
▪ Long-term effect was unknown 
▪ High coefficient of friction 
▪ PDMS 
o cyclic silicone monomer can contaminate the 
product 
o Hydrophobic 
o Tend to absorb protein 
▪ Parylene 
o high absorption rate  
o poor adhesion 
o low mechanical strength 
 
[47] 
PU ▪ high durability 
▪ biocompatible and hemocompatible 
▪ low water permeability  
▪ good biostability 
▪ low coefficient of friction 
▪ in vivo degradation 
▪ metal oxidation 
[47] 
 
Contraceptive implant development 
The first contraceptive implant was established by The Population 
Council and permitted in 1983 in Finland, namely Norplant®. 
Norplant® consists of six-rods, each rod contained levonorgestrel 
with dose of 36 mg. Levonorgestrel was a progestin produced 
synthetically that have similarity with the natural progesterone in 
females. At 2008, production of Norplant® was stopped because of 
the launching of new generation product. Those products were two-
rods implants (Sino-implant (II)® and Jadelle®) and single-rod 
implants, (Nexplanon®/Implanon NXT® and Implanon®). Those 
new implants were easier to be inserted and retrieved [29, 54]. 
At 1996, Jadelle® was agreed by the United States Food and Drug 
Administration (USFDA). It comprises two rods; each rod contained 
levonorgestrel with dose 75 mg. At the same year, a similar product 
(number of rod and amount of levonorgestrel) was introduced in 
China, namely Sino-implant (II)®. Two years later, Implanon® first 
introduced but USFDA approval announced in 2006. It contains 68 
mg of etonogestrel (also progestin) [33, 55].  
The new generation single-rod implant, Implanon NXT®, have the 
similarity with Implanon® in design but it was more radio-opaque. 
Because of radio-opacity of Implanon NXT, if the implant inserted 
too deep in the skin and when removal procedure the rod was very 
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difficult to trace, it can be easily detected using x-ray. Implanon NXT® 
also has a trocar, the operating instruments used to insert the rod [6]. 
In situ forming implants is one of the latest implant developments. Rapid 
development of this implants was because of its several advantages, such 
as ease of application, prolong of drug duration, reduced the dosage, 
improve patient compliance, and the main advantage is to reduce the 
invasive procedure. Prior to injection, the implant is in a liquid state, 
whereas once injected into the body, the polymer solution solidified to 
semisolid state and release the drug slowly. There were several ways in 
solidifying process of the implant, including cross-linking, solvent-
removal, temperature change, pH, and more [56, 57]. 
PLGA is the most widely used biodegradable and biocompatible 
polymer as a carrier in a sustained drug delivery system. PLGA 
dissolves completely in N-methyl-2-pyrrolidone (NMP) or other 
organic solvents and precipitates when injected into the water 
environment, in this case, body fluids. This is because the organic 
solvent diffuses out and the water penetrates into the polymer 
matrix. Both hydrophilic drugs and hydrophobic drugs can be easily 
dissolved or suspended into the PLGA solution, and no other 
treatment is required for in situ compound forming implants, which 
is particularly suitable for delivery of drugs of proteins and peptides 
[56].
 
Table 3: Recent advances in implant technology 




alpha 1 (Tα1) 
PLGA Tα1 was encapsulated by chitosan and mixed with a high concentration of PLGA to form a 






PLGA PLGA as biodegradable polymer was used to prolong the activity of asenapine maleate in 
Schizoprenia and bipolar disorder treatment. The drug was released for 21 d and showed an 
antipsychotic effect. 
[58] 
Lupron Leuprolide Saber Depot 
Technology 
Saber delivery system used a highly viscous carrier (i.e. sucrose acetate isobutyrate). It can 
be injected in a liquid form after mixed with the drug and solidified in the body. Because the 
polymer used are biodegradable, it was not required for removal procedures. 
[59] 
Atridox Doxycycline  Atrigel 
system 
Atridox was designed as a locally applied antibiotic for periodontal management. There was 
2 coupled syringe contained atrigel and drug powder (doxycycline). When the syringes were 
mixed, Atridox becomes a gel and easy to apply in the target area. Doxycycline would release 
for 21 d, and Atridox would be absorbed into the body, thus removal procedure was not 
required. 
[59] 
OncoGel Paclitaxel  Regel depot 
technology 
The product reconstituted using ReGel and formed a liquid because it was below the gelation 
temperature. After injection, Regel system quickly changes into biodegradable implants. 
Polymer used in this system was thermosensitive polymers. 
[59] 
 
Opportunities to develop contraceptive implant dosage forms 
Nowadays, most preparations are designed relatively easily and 
made into oral dosage forms. However, this design still causes some 
problems such as patient compliance, design complexity, and also 
cost system that would control the rate, dosage, and delivery 
towards specific targets. In the end, we need to design a dosage form 
that didn’t have a fluctuation of plasma concentration of the drug 
due to patient non-compliance. Finally, the implant could overcome 
that problem. But the challenge was how to design the implant that 
more effective in terms of cost and patient-friendly (smaller, non-
invasive, and specific targets) [9]. There were challenges in 
designing implant such as:  
• Operating time: duration of action needs to be longer, especially 
for chronic disorders treatment [60]. 
• Loading volume and drug reservoir size: it is impossible to surge 
the device size to put up a large reservoir. The device should be 
designed as small as possible thus the side effects into surrounding 
tissues are fewer [61].  
• Biocompatibility: the material should be well-respond to the 
immune system so the risks (allergy, inflammation) could be 
reduced [62,63] 
Application of contraceptive implants requires a trained person 
because it is still invasive, where the implant should be inserted and 
removed. The new generation of contraceptive implants, Implanon 
NXT, added the ease of detection of the implant site. The 
opportunities that can be developed from the contraceptive implant 
such as by using the concept of in situ forming implants so insertion 
by the operative procedure can be replaced only by an injection. 
Then we should develop the implants using biodegradable polymers 
to solve implant removal problem. 
CONCLUSION 
Contraceptives implant are hormonal contraceptives containing 
low-dose progestin,which is inserted subdermally with long-term 
duration. Contraceptive implants prevent the occurrence of 
pregnancy by making the cervical mucus thicker and disrupting the 
formation of the endometrium. Some of the benefits of implant 
contraception include its very high effectivity. Thus, contraceptive 
implants are still on a great demand in the market to overcome 
unintended pregnancies and control human growth population. And 
in the end, its benefit is to improve the quality of life. Contraceptive 
implants in the future can undergo technological developments by 
using the concept of in situ forming implants and biodegradable 
polymers as the carrier so that no removal action is required. 
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